GT Biopharma, Inc.
GTBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000109657
No open-market purchases or sales by GT Biopharma, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $1.02M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in GT Biopharma, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- +1 vs. Q4 2024
- Shares held
- 99.7K
- −1.15M (−92.0%) vs. Q4 2024
- Total value
- $220.5K
- −$58.6K (−21.0%) vs. Q4 2024
- New holders
- 3
- 2 more added
- Sold out
- 2
- 5 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GTBP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 59 | $1.02M |
| Q1 2026 | 42 | $656.7K |
| Q4 2025 | 38 | $373.7K |
| Q3 2025 | 21 | $222.2K |
| Q2 2025 | 21 | $711.3K |
| Q1 2025 | 20 | $220.5K |
| Q4 2024 | 19 | $279.1K |
| Q3 2024 | 16 | $203.8K |
| Q2 2024 | 17 | $296.8K |
| Q1 2024 | 17 | $348.6K |
| Q4 2023 | 34 | $893.1K |
| Q3 2023 | 33 | $849.9K |
| Q2 2023 | 37 | $1.11M |
| Q1 2023 | 36 | $3.05M |
| Q4 2022 | 36 | $5.62M |
| Q3 2022 | 35 | $4.36M |
| Q2 2022 | 48 | $9.28M |
| Q1 2022 | 58 | $12.9M |
| Q4 2021 | 55 | $16.7M |
| Q3 2021 | 54 | $32.1M |
| Q2 2021 | 50 | $69.9M |
| Q1 2021 | 21 | $3.98M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding GT Biopharma, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 1 | $2 | 0.00% | 00.0% | Unchanged |
| Front Row Advisors LLC | 1 | $2 | 0.00% | +1 | New |
| Allworth Financial LP | 1 | $3 | 0.00% | −1−50.0% | Reduced |
| BNP Paribas Arbitrage, SA | 6 | $13 | 0.00% | 00.0% | Unchanged |
| Farther Finance Advisors, LLC | 6 | $14 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 8 | $17 | 0.00% | −8−50.0% | Reduced |
| Blue Bell Private Wealth Management, LLC | 10 | $22 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 27 | $59 | 0.00% | 00.0% | Unchanged |
| GHP Investment Advisors, Inc. | 33 | $71 | 0.00% | +33 | New |
| Tower Research Capital LLC (TRC) | 918 | $1.97K | 0.00% | −1,999−68.5% | Reduced |
| Newbridge Financial Services Group, Inc. | 1,750 | $3.76K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 2,559 | $5.50K | 0.00% | −2,437−48.8% | Reduced |
| Advisor Group Holdings, Inc. | 2,706 | $5.82K | 0.00% | +61+2.3% | Added |
| Morgan Stanley | 3,533 | $7.60K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 9,737 | $20.9K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 10,013 | $21.5K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 10,504 | $23.5K | 0.00% | 00.0% | Unchanged |
| Bank of Montreal | 14,651 | $32.8K | 0.00% | −14,300−49.4% | Reduced |
| Citadel Advisors LLC | 20,138 | $45.1K | 0.00% | +20,138 | New |
| Geode Capital Management, LLC | 23,086 | $51.7K | 0.00% | +8,187+54.9% | Added |
| VSM Wealth Advisory, LLC | 0 | $0 | 0.00% | −501−100.0% | Sold out |
| DekaBank Deutsche Girozentrale | 0 | $0 | 0.00% | −1,154,867−100.0% | Sold out |